- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07692321
Co-designing Enhanced Models of Care for First Nations Children at Risk for Childhood-onset Type 2 Diabetes
Co-designing Enhanced Models of Care for First Nations Children at Risk for Childhood-onset Type 2 Diabetes: The Next Generation Birth Cohort.
Studieoversikt
Status
Detaljert beskrivelse
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Brandy A Wicklow, MD, MSc
- Telefonnummer: 204-787-1222
- E-post: bwicklow@hsc.mb.ca
Studer Kontakt Backup
- Navn: Elizabeth AC Sellers, MD, MSc
- Telefonnummer: 204-787-3011
- E-post: esellers@hsc.mb.ca
Studiesteder
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 3P4
- Children's Hospital Research Institute of Manitoba/University of Manitoba
-
Ta kontakt med:
- Brandy A Wicklow, MD, MSc
- Telefonnummer: 204781222
- E-post: bwicklow@hsc.mb.ca
-
Ta kontakt med:
- Research Coordinator
- Telefonnummer: 2042723064
- E-post: NextGenStudy@chrim.ca
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria for the breastfeeding program:
- Pregnant women with type 2 diabetes or no diabetes.
- From self-identified Indigenous heritage (e.g., Cree, Oji-Cree, Métis, Anishinaabe, etc.) residing in the four Anisininew communities in the Island Lake region.
- Are delivering in Manitoba.
- Mother/Father and children must be biological family members.
Exclusion Criteria from the breastfeeding program:
- Parents or children with type 1 diabetes.
- Residing outside of Manitoba.
Inclusion criteria for the CGM pro
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Co-develop and implement a community-based perinatal education and support program using navigators
The implementation of a community-based navigator to facilitate multiple points of pre and post-partum contact as well as individualized connection to preexisting and co-developed urban and northern pre- and post-natal supports, will increase rates of initiation and duration (≥6 month) of breastfeeding in the NextGen mothers from 58% to ≥75%.
|
Co-develop and implement a community-based perinatal education and support program using navigators to support breast feeding, maternal nutrition and activity, and early infancy/childhood nutrition and activity.
|
|
Extend the scope of the NextGen Cohort
Community based point of care HbA1c testing will improve access to annual screening for pre-diabetes and diabetes in the Next Gen Cohort.
CGM can detect early dysglycemia (below the threshold for the diagnosis of prediabetes) in young children at high risk for childhood-onset T2D.
In addition, we hypothesize that CGM use will be well tolerated and feasible in young children.
|
This will allow study participants to conduct earlier and more frequent screening for early dysglycemia, prediabetes and T2D.
We will investigate the use of continuous glucose monitoring (CGM) to detect early dysglycemia in the Next Gen cohort.
|
|
Co-develop and implement community led land-based programming for parent(s) and preschool children
Land-based community programming for caregivers and children aged 4-5 years is feasible and will encourage healthy nutrition choices and physical activity.
Ultimately, we hypothesize that this will improve the health and well-being of this high-risk population and improve cardiometabolic health.
|
Co-develop and implement community led land-based programming for parent(s) and preschool children aged 4-5 years to encourage traditional nutrition and activities to maintain wellness.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of mothers who initiate breastfeeding
Tidsramme: 3 years
|
This will be for for both groups experiencing and not experiencing diabetes during the pregnancy, exclusivity of breastfeeding and breastfeeding continuation at 1, 3 and 6 months.
In addition, we will examine the growth trajectories of infants who are breastfed and compare them to infants who are not breastfed (from historical NextGen Cohort follow up and the current project).
|
3 years
|
|
Number of eligible children in the NextGen Cohort screened per community
Tidsramme: 3 years
|
This is a feasibility pilot to determine if participants will be screened more frequently once there are point of care HbA1C machines in each community. Qualitative data on the feasibility and implementation of the screening program via interviews with the community health care workers and NextGen families to determine facilitators and barriers to screening in community and areas of improvement for the program. |
3 years
|
|
Percentage of sensor time with glucose > 7.8 mmol/L
Tidsramme: 3 years
|
This is to determine the feasibility of using CGM with 6 and 7 year old children.
SD of sensor glucose levels (a summary measure of glycemic variability - amplitude, frequency and duration of fluctuation in glucose measurement) and 2. tolerability and feasibility of CGM use in this population.
|
3 years
|
|
Number of times the land-based wellness program ran
Tidsramme: 3 years
|
Feasibility of establishing and implementing this program will be assessed by metrics including how often the program ran (bench marked against number of sessions planned), and number of children participating (benchmarked against number eligible).
|
3 years
|
|
Number of children who attend the land-based wellness programming
Tidsramme: 3 years
|
3 years
|
|
|
Number of young adult leaders hired for the land-based wellness program
Tidsramme: 3 years
|
We anticipate that another key outcome will be capacity building for young adult leaders who will work alongside Elders and develop skills in leadership, youth health and wellness, program evaluation, and land-based curriculum development
|
3 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of mothers who enroll and participate in the breastfeeding navigator-based program
Tidsramme: 3 years
|
3 years
|
|
|
Number classes attended by mothers who participate in the breastfeeding navigator-based program
Tidsramme: 3 years
|
3 years
|
|
|
Qualitative review of the land-based wellness program
Tidsramme: 3 years
|
Barriers and facilitators of program success will be co-determined by Anisininew leaders through the evaluative process, and may include qualitative interviews with family participants and leaders and/or sharing circles lead by Elders and Knowledge keepers.
|
3 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Brandy A Wicklow, MD, MSc, University of Manitoba, Children's Hospital Research Institute of Manitoba
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Sykdommer i det endokrine systemet
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Metabolske sykdommer
- Graviditetskomplikasjoner
- Glukosemetabolismeforstyrrelser
- Sukkersyke
- Ernæringsmessige og metabolske sykdommer
- Diabetes, svangerskap
- Diabetes mellitus, type 2
- Undersøkelsesteknikker
- Terapeutikk
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Pasientbehandling
- Helsetjenester
- Helsetjenester arbeidsstyrke og tjenester
- Reproduktive fysiologiske fenomener
- Reproduksjons- og urinfysiologiske fenomener
- Blodkjemisk analyse
- Kliniske kjemitester
- Diagnostiske teknikker, endokrin
- Overvåking, fysiologisk
- Postpartum periode
- Palliativ omsorg
- Kontinuerlig glukoseovervåking
- Amming
Andre studie-ID-numre
- 5308
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .